Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Cellular Signalling

Volumn 26, Issue 9, 2014, Pages 2016-2029

  Schafer, P H ^a   Parton, A ^a   Capone, L ^a   Cedzik, D ^a   Brady, H ^a   Evans, J F ^b   Man, H W ^a   Muller, G W ^c   Stirling, D I ^d   Chopra, R ^a  

^a CELGENE CORPORATION   (United States)

^b Department of Biology PharmAkea ^*  (United States)

^c Rancho Santa Fe   (United States)

^d BioTheryX Inc   (United States)

Author keywords

Apremilast; Phosphodiesterase inhibitor; Preclinical drug evaluation; Psoriasis; Psoriatic arthritis; Spondyloarthropathies

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; ALPHA INTERFERON; APREMILAST; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CILOMILAST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; L SELECTIN; LENALIDOMIDE; PHOSPHODIESTERASE IV; POMALIDOMIDE; ROFLUMILAST; ROLIPRAM; THALIDOMIDE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; CYTOKINE; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN BINDING;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; FERRET; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LUNG DISEASE; LUNG NEUTROPHILIA; MALE; MOLECULAR CLONING; MOUSE; NAUSEA AND VOMITING; NEUTROPHILIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TRANSGENIC MOUSE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; JURKAT CELL LINE; LUNG DISEASES; METABOLISM; VOMITING;

ADAPTIVE IMMUNITY; ANIMALS; B-LYMPHOCYTES; CELL LINE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; HUMANS; IMMUNITY, INNATE; JURKAT CELLS; LUNG DISEASES; MALE; MICE; MICE, TRANSGENIC; PHOSPHODIESTERASE 4 INHIBITORS; PROTEIN BINDING; T-LYMPHOCYTES; THALIDOMIDE; VOMITING;

EID: 84902507264     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2014.05.014     Document Type: Article

References (60)

1. Lowes M.A., Bowcock A.M., Krueger J.G. Nature 2007, 445:866-873.
2. Nestle F.O., Kaplan D.H., Barker J. N. Engl. J. Med. 2009, 361:496-509.
3. Schafer P. Biochem. Pharmacol. 2012, 83:1583-1590.
4. Conti M., Beavo J. Annu. Rev. Biochem. 2007, 76:481-511.
5. Serezani C.H., Ballinger M.N., Aronoff D.M., Peters-Golden M. Am. J. Respir. Cell Mol. Biol. 2008, 39:127-132.
6. Zambon A.C., Zhang L., Minovitsky S., Kanter J.R., Prabhakar S., Salomonis N., Vranizan K., Dubchak I., Conklin B.R., Insel P.A. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8561-8566.
7. Ollivier V., Parry G.C., Cobb R.R., de Prost D., Mackman N. J. Biol. Chem. 1996, 271:20828-20835.
8. Jimenez J.L., Punzon C., Navarro J., Munoz-Fernandez M.A., Fresno M. J. Pharmacol. Exp. Ther. 2001, 299:753-759.
9. Francis S.H., Blount M.A., Corbin J.D. Physiol. Rev. 2011, 91:651-690.
10. Salari P., Abdollahi M. Expert. Opin. Investig. Drugs 2012, 21:261-264.
11. Schafer P.H. Presented at: 8th International Congress on Autoimmunity; May 9-13; Granada, Spain 2012.
12. Houslay M.D. Trends Biochem. Sci. 2010, 35:91-100.
13. Houslay M.D., Baillie G.S., Maurice D.H. Circ. Res. 2007, 100:950-966.
14. Houslay M.D., Schafer P., Zhang K.Y. Drug Discov. Today 2005, 10:1503-1519.
15. Schafer P.H., Parton A., Gandhi A.K., Capone L., Adams M., Wu L., Bartlett J.B., Loveland M.A., Gilhar A., Cheung Y.-F., Baillie G.S., Houslay M.D., Man H.-W., Muller G.W., Stirling D.I. Br. J. Pharmacol. 2010, 159:842-855.
16. Otezla (apremilast) [package insert] March 2014, Celgene Corporation, Summit, NJ.
17. Daliresp (roflumilast) [package insert] August 2013, Forest Pharmaceuticals, Inc., St. Louis, MO.
18. Man H.-W., Schafer P., Wong L.M., Patterson R.T., Corral L.G., Raymon H., Blease K., Leisten J., Shirley M.A., Tang Y., Babusis D.M., Chen R., Stirling D., Muller G.W. J. Med. Chem. 2009, 52:1522-1524.
19. Capone L., Rogovitz A., Gandhi A.K., Schafer P.H. Arthritis Rheum. 2011, 63(10 Suppl.):1844.
20. Gottlieb A.B., Strober B., Krueger J.G., Rohane P., Zeldis J.B., Hu C.C., Kipnis C. Curr. Med. Res. Opin. 2008, 24:1529-1538.
21. McCann F.E., Palfreeman A.C., Andrews M., Perocheau D.P., Inglis J.J., Schafer P., Feldman M., Williams R.O., Brennan F.M. Arthritis Res. Ther. 2010, 12:R107.
22. Wu L., Adams M., Parton S., Schafer P.H. Arthritis Rheum. 2012, 64:S20.
23. Adams M., Schafer P.H. Arthritis Rheum. 2012, 64:S17.
24. Gottlieb A.B., Matheson R.T., Menter A., Leonardi C.L., Day R.M., Hu C.C., Schafer P.H., Krueger J.G. J. Drugs Dermatol. 2013, 12:888-897.
25. Papp K., Cather J., Rosoph L., Sofen H., Langley R.G., Matheson R.T., Hu A., Day R.M. Lancet 2012, 380:738-746.
26. Schett G., Wollenhaupt J., Papp K., Joos R., DeVlam K.L., Rodrigues J.F., Vessey A., Hu C.C., Stevens R. Arthritis Rheum. 2012, 64:3156-3167.
27. Celgene Biopharmaceutical Apremilast PALACE program demonstrates robust and consistent statistically significant clinical benefit across three pivotal phase III studies (PALACE-1, 2 & 3) in psoriatic arthritis [press release] Available at:, (Accessed September 10, 2013). http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1732178&highlight=
28. Hatemi G., Melikoglu M., Tunc R., Korkmaz C., Ozturk B.T., Mat C., Merkel P.A., Calamia K., Liu Z., Pineda L., Stevens R.M., Yazici H., Yazici Y. Arthritis Rheum. 2013, 65(10 Suppl.):S322.
29. Reich K., Papp K., Leonardi C., Kircik L., Chimenti S., Hu C.C., Stevens R.M., Day R.M., Griffiths C.E.M. Presented at: Annual Meeting of the American Academy of Dermatology; March 1-5, Miami, FL 2013.
30. Kavanaugh A., Mease P.J., Adebajo A., Wollenhaupt J., Hu C.C., Shah K., Stevens R.M., Gomez-Reino J.J. Presented at: Annual Congress of the European League Against Rheumatism; June 12-15, Madrid, Spain 2013.
31. Cutolo M., Myerson G.E., Fleischmann R.M., Liote F., Diaz-Gonzalez F., Van den Bosch F., Marzo-Ortega H., Feist E., Shah K., Hu C.C., Stevens R.M., Poder A. Arthritis Rheum. 2013, 65(10 Suppl.):S346-S347.
32. Edwards C.J., Blanco F.J., Crowley J., Hu C.C., Stevens R.M., Birbara C.A. Arthritis Rheum. 2013, 65(10 Suppl.):S132.
33. Wells A.F., Edwards C.J., Adebajo A.O., Kivitz A.J., Bird P., Shah K., Hu C.C., Stevens R.M., Aelion J.A. Presented at: Annual Scientific Meeting of the American College of Rheumatology; October 26-30, San Diego, CA 2013.
34. Nemoz G., Sette C., Conti M. Mol. Pharmacol. 1997, 51:242-249.
35. Sullivan M., Olsen A.S., Houslay M.D. Cell. Signal. 1999, 11:735-742.
36. McLaughlin M.M., Cieslinski L.B., Burman M., Torphy T.J., Livi G.P. J. Biol. Chem. 1993, 268:6470-6476.
37. Nemoz G., Zhang R., Sette C., Conti M. FEBS Lett. 1996, 384:97-102.
38. Sullivan M., Rena G., Begg F., Gordon L., Olsen A.S., Houslay M.D. Biochem. J. 1998, 333(Pt 3):693-703.
39. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H. Science 2010, 327:1345-1350.
40. Adams C.L., Rush C.M., Smith K.M., Garside P. Methods Mol. Biol. 2004, 239:133-146.
41. Barber R., Baillie G.S., Bergmann R., Shepherd M.C., Sepper R., Houslay M.D., Heeke G.V. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:L332-L343.
42. Huston E., Houslay T.M., Baillie G.S., Houslay M.D. Biochem. Soc. Trans. 2006, 34:504-509.
43. Molostvov G., Morris A., Rose P., Basu S., Muller G. Br. J. Haematol. 2004, 124:366-375.
44. Lopez-Girona A., Mendy D., Ito T., Miller K., Gandhi A.K., Kang J., Karasawa S., Carmel G., Jackson P., Abbasian M., Mahmoudi A., Cathers B., Rychak E., Gaidarova S., Chen R., Schafer P.H., Handa H., Daniel T.O., Evans J.F., Chopra R. Leukemia 2012, 26:2326-2335.
45. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., Patterson R.T., Stirling D.I., Kaplan G. J. Immunol. 1999, 163:380-386.
46. McKenna J.M., Muller G.W. Cyclic Nucleotide Phosphodiesterases in Health and Disease 2007, 667-699. CRC Press/Taylor & Francis, Boca Raton, FL. J.A. Beavo, S.H. Francis, M.D. Houslay (Eds.).
47. Kodimuthali A., Jabaris S.S., Pal M. J. Med. Chem. 2008, 51:5471-5489.
48. Tenor H., Hatzelmann A., Beume R., Lahu G., Zech K., Bethke T.D. Handb. Exp. Pharmacol. 2011, 85-119.
49. Muller G.W., Shire M.G., Wong L.M., Corral L.G., Patterson R.T., Chen Y., Stirling D.I. Bioorg. Med. Chem. Lett. 1998, 8:2669-2674.
50. Wu L., Adams M., Carter T., Chen R., Muller G., Stirling D., Schafer P., Bartlett J.B. Clin. Cancer Res. 2008, 14:4650-4657.
51. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Johnson-Huang L.M., Nograles K.E., White T.R., Pierson K.C., Lentini T., Suarez-Farinas M., Lowes M.A., Krueger J.G. J. Allergy Clin. Immunol. 2010, 125:1261-1268.
52. Krueger J.G., Fretzin S., Suarez-Farinas M., Haslett P.A., Phipps K.M., Cameron G.S., McColm J., Katcherian A., Cueto I., White T., Banerjee S., Hoffman R.W. J. Allergy Clin. Immunol. 2012, 130:145-154.
53. Bouaziz J.D., Yanaba K., Tedder T.F. Immunol. Rev. 2008, 224:201-214.
54. Williams J.J., Palmer T.M. Biochem. Soc. Trans. 2012, 40:215-218.
55. Parry G.C., Mackman N. J. Immunol. 1997, 159:5450-5456.
56. Takahashi N., Tetsuka T., Uranishi H., Okamoto T. Eur. J. Biochem. 2002, 269:4559-4565.
57. Schafer P.H. Presented at: 41st Annual Meeting of the European Society for Dermatological Research; September 7-12, Barcelona, Spain 2011.
58. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., Gottlieb A.B., Koo J.Y.M., Lebwohl M., Lim H.W., Van Voorhees A.S., Beutner K.R., Bhushan R. J. Am. Acad. Dermatol. 2009, 61:451-485.
59. Mease P.J., Kavanaugh A., Gladman D.D., Adebajo A.O., Gomez-Reino J.J., Wollenhaupt J., Cutolo M., Schett G., Lespessailles E., Shah K., Hu C.C., Stevens R.M., Edwards C.J., Birbara C.A. Arthritis Rheum. 2013, 65(10 Suppl.):S131-S132.
60. Celgene International Sarl Apremilast achieves statistical significance for the primary endpoint of the first phase III study (PALACE-1) in patients with psoriatic arthritis [press release] Available at:, (Accessed August 6, 2013). http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1714113&highlight=